kdr: % alive (live/total) | ace 1R: % alive (live/total) | ||||||
---|---|---|---|---|---|---|---|
Treatments | SS | RS | RR | SS | RS | RR | |
First trial (single intervention) | |||||||
1 | Pyrethroid WL | 33 (1/3) | 73 (16/22) | 65 (57/88) | - | - | - |
2 | P-methyl WL (walls only) | 0 (0/3) | 55 (6/11) | 29 (10/34) | 15 (3/20) | 28 (22/78) | - |
3 | P-methyl NWH (walls only) | 75 (3/4) | 0 (0/2) | 50 (13/26) | 25 (3/12) | 59 (30/51) | 0 (0/4) |
4 | P-methyl WL (walls and ceiling) | 0 (0/2) | 75 (3/4) | 41 (13/32) | 15 (2/13) | 51 (22/43) | - |
5 | P-methyl NWH (walls and ceiling) | 0 (0/1) | 55 (6/11) | 30 (6/20) | 0 (0/9) | 43 (24/56) | 25 (1/4) |
Second trial (combined intervention) | |||||||
1 | Control (untreated net) | 100 (2/2) | 77 (10/13) | 83 (64/77) | 70 (7/10) | 85 (66/78) | 100 (4/4) |
2 | LLIN | 0 (0/2) | 43 (10/23) | 40 (31/78) | - | - | - |
3 | P-methyl WL | 0 (0/2) | 50 (6/12) | 53 (18/34) | 17 (1/6) | 70 (23/33) | 40 (2/5) |
4 | P-methyl NWH | 0 (0/1) | 67 (10/15) | 50 (14/28) | 43 (3/7) | 56 (19/34) | 50 (2/4) |
5 | P-methyl WL + LLIN | 0 (0/2) | 20 (1/5) | 23 (10/44) | 20 (2/10) | 18 (7/39) | 50 (2/4) |
6 | P-methyl NWH + LLIN | 0 (0/2) | 67 (6/9) | 50 (13/26) | 17 (1/6) | 56 (15/27) | 75 (3/4) |